03:53 PM EDT, 08/20/2024 (MT Newswires) -- Dr. Reddy's Laboratories (RDY) said Tuesday that the company and its contract research, development and manufacturing organization Aurigene Pharmaceutical Services signed a nonbinding memorandum of understanding with Kainomyx to develop and commercialize an affordable anti-malarial drug.

Under the partnership, Kainomyx will lead the technical strategy along with related aspects of discovery and clinical trials while Aurigene will develop cost-effective and scalable drug chemistry and Dr. Reddy's will provide regulatory and market access expertise.

Financial terms were not disclosed.

Price: 83.44, Change: +0.67, Percent Change: +0.81